126 related articles for article (PubMed ID: 16990199)
1. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?
de Boer W; de Wit N; Geldof H; Hazelhoff B; Bergmans P; Smout A; Tytgat G
Scand J Gastroenterol; 2006 Oct; 41(10):1147-54. PubMed ID: 16990199
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
Cheong JH; Kim GH; Lee BE; Choi MK; Moon JY; Ryu DY; Kim DU; Song GA
Scand J Gastroenterol; 2011 Jul; 46(7-8):789-96. PubMed ID: 21615222
[TBL] [Abstract][Full Text] [Related]
6. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Calleja JL; Suarez M; De Tejada AH; Navarro A;
Dig Dis Sci; 2005 Mar; 50(3):432-9. PubMed ID: 15810621
[TBL] [Abstract][Full Text] [Related]
9. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Bytzer P; Morocutti A; Kennerly P; Ravic M; Miller N;
Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
[TBL] [Abstract][Full Text] [Related]
10. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
[TBL] [Abstract][Full Text] [Related]
12. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori.
Fallone CA; Barkun AN; Mayrand S; Wakil G; Friedman G; Szilagyi A; Wheeler C; Ross D
Aliment Pharmacol Ther; 2004 Oct; 20(7):761-8. PubMed ID: 15379836
[TBL] [Abstract][Full Text] [Related]
13. Rabeprazole for the treatment of acid-related disorders.
Marelli S; Pace F
Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):423-35. PubMed ID: 22928894
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Kinoshita Y; Ashida K; Hongo M;
Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
[TBL] [Abstract][Full Text] [Related]
16. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
Fan YH; Lü B; Zhan LX; Zhang L
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823
[TBL] [Abstract][Full Text] [Related]
17. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East.
Wu JC; Sung JJ; Ng EK; Go MY; Chan WB; Chan FK; Leung WK; Choi CL; Chung SC
Am J Gastroenterol; 1999 Jul; 94(7):1790-4. PubMed ID: 10406236
[TBL] [Abstract][Full Text] [Related]
19. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
Watson TJ; Peters JH
Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
